0.46
+0.1444(+45.77%)
Currency In USD
| Previous Close | 0.32 |
| Open | 0.48 |
| Day High | 0.67 |
| Day Low | 0.45 |
| 52-Week High | 9.18 |
| 52-Week Low | 0.28 |
| Volume | 206.58M |
| Average Volume | 224,875 |
| Market Cap | 13.03M |
| PE | -22.99 |
| EPS | -0.02 |
| Moving Average 50 Days | 0.39 |
| Moving Average 200 Days | 1.4 |
| Change | 0.14 |
If you invested $1000 in Curanex Pharmaceuticals Inc Common Stock (CURX) since IPO date, it would be worth $114.4 as of February 26, 2026 at a share price of $0.46. Whereas If you bought $1000 worth of Curanex Pharmaceuticals Inc Common Stock (CURX) shares 6 months ago, it would be worth $114.4 as of February 26, 2026 at a share price of $0.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Curanex Provides Operational Update on Key Regulatory Milestones
GlobeNewswire Inc.
Feb 25, 2026 1:00 PM GMT
Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage pharmaceut
Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement
GlobeNewswire Inc.
Oct 22, 2025 11:00 AM GMT
Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental-stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory disea
Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters
GlobeNewswire Inc.
Sep 12, 2025 6:46 PM GMT
Jericho, New York, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory dise